Alexandra Crowe1, Wei Zheng2, Jonathan Miller1, Sonia Pahwa1, Khondoker Alam1, Kar-Ming Fung2, Erin Rubin2, Feng Yin2, Kai Ding3, Wei Yue4. 1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Avenue, Oklahoma City, OK, 73117, USA. 2. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4. Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Avenue, Oklahoma City, OK, 73117, USA. Wei-Yue@ouhsc.edu.
Abstract
PURPOSE: Membrane transport protein organic anion transporting polypeptide (OATP) 1B1 mediates hepatic uptake of many drugs (e.g. statins). The OATP1B1 c.521 T > C (p. V174A) polymorphism has reduced transport activity. Conflicting in vitro results exist regarding whether V174A-OATP1B1 has reduced plasma membrane localization; no such data has been reported in physiologically relevant human liver tissue. Other potential changes, such as phosphorylation, of the V174A-OATP1B1 protein have not been explored. Current studies characterized the plasma membrane localization of V174A-OATP1B1 in genotyped human liver tissue and cell culture and compared the phosphorylation status of V174A- and wild-type (WT)-OATP1B1. METHODS: Localization of V174A- and WT-OATP1B1 were determined in OATP1B1 c.521 T > C genotyped human liver tissue (n = 79) by immunohistochemistry and in transporter-overexpressing human embryonic kidney (HEK) 293 and HeLa cells by surface biotinylation and confocal microscopy. Phosphorylation and transport of OATP1B1 was determined using 32P-orthophosphate labeling and [3H]estradiol-17β-glucuronide accumulation, respectively. RESULTS: All three methods demonstrated predominant plasma membrane localization of both V174A- and WT-OATP1B1 in human liver tissue and in cell culture. Compared to WT-OATP1B1, the V174A-OATP1B1 has significantly increased phosphorylation and reduced transport. CONCLUSIONS: We report novel findings of increased phosphorylation, but not impaired membrane localization, in association with the reduced transport function of the V174A-OATP1B1.
PURPOSE: Membrane transport protein organic anion transporting polypeptide (OATP) 1B1 mediates hepatic uptake of many drugs (e.g. statins). The OATP1B1 c.521 T > C (p. V174A) polymorphism has reduced transport activity. Conflicting in vitro results exist regarding whether V174A-OATP1B1 has reduced plasma membrane localization; no such data has been reported in physiologically relevant human liver tissue. Other potential changes, such as phosphorylation, of the V174A-OATP1B1 protein have not been explored. Current studies characterized the plasma membrane localization of V174A-OATP1B1 in genotyped human liver tissue and cell culture and compared the phosphorylation status of V174A- and wild-type (WT)-OATP1B1. METHODS: Localization of V174A- and WT-OATP1B1 were determined in OATP1B1 c.521 T > C genotyped human liver tissue (n = 79) by immunohistochemistry and in transporter-overexpressing humanembryonic kidney (HEK) 293 and HeLa cells by surface biotinylation and confocal microscopy. Phosphorylation and transport of OATP1B1 was determined using 32P-orthophosphate labeling and [3H]estradiol-17β-glucuronide accumulation, respectively. RESULTS: All three methods demonstrated predominant plasma membrane localization of both V174A- and WT-OATP1B1 in human liver tissue and in cell culture. Compared to WT-OATP1B1, the V174A-OATP1B1 has significantly increased phosphorylation and reduced transport. CONCLUSIONS: We report novel findings of increased phosphorylation, but not impaired membrane localization, in association with the reduced transport function of the V174A-OATP1B1.
Authors: Shindu C Thomas; Tushar Madaan; Nitin S Kamble; Nabil A Siddiqui; Giovanni M Pauletti; Nalinikanth Kotagiri Journal: Adv Healthc Mater Date: 2021-11-16 Impact factor: 9.933
Authors: Elizabeth R Hayden; Mingqing Chen; Kyle Z Pasquariello; Alice A Gibson; James J Petti; Shichen Shen; Jun Qu; Su Sien Ong; Taosheng Chen; Yan Jin; Muhammad Erfan Uddin; Kevin M Huang; Aviv Paz; Alex Sparreboom; Shuiying Hu; Jason A Sprowl Journal: Clin Cancer Res Date: 2021-03-04 Impact factor: 12.531
Authors: Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero Journal: Int J Mol Sci Date: 2020-04-20 Impact factor: 5.923
Authors: Wilma Kiander; Kati-Sisko Vellonen; Melina M Malinen; Mikko Gynther; Marja Hagström; Madhushree Bhattacharya; Seppo Auriola; Jan B Koenderink; Heidi Kidron Journal: Pharm Res Date: 2021-10-13 Impact factor: 4.200
Authors: Sayani Bhattacharjee; Matthew J Sullivan; Rebecca R Wynn; Alex Demagall; Andrew S Hendrix; Puneet Sindhwani; Firas G Petros; Nagalakshmi Nadiminty Journal: BMC Cancer Date: 2022-03-23 Impact factor: 4.430